Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Meanwhile, Pfizer reckons it's found the right dose for its KAT6.
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
Roche’s PI3Kα inhibitor continues to pull away from Novartis’s Piqray.
Petosemtamab and ficerafusp alfa are among the biologicals to be featured at ASCO.
Herthena-Lung02 data are an ASCO shocker.
A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.
